Eribulin Mesylate
Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin is also known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389. It is used to treat certain patients with breast cancer and liposarcoma.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Eribulin Mesylate |
|---|---|
| Iupac 化学名称 | 11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3':5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5(4H)-one, 2-((2S)-3- amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, 2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate |
| 同义词 | Eribulin Mesylate; E7389; E-7389; E 7389; ER-086526; ER 086526; ER086526; |
| 英文同义词 | Eribulin Mesylate; E7389; E-7389; E 7389; ER-086526; ER 086526; ER086526; |
| 分子式 | C41H63NO14S |
| 分子量 | 826.00 |
| Smile | InChI=1S/C40H59NO11.CH4O3S/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41;1-5(2,3)4/h19,23-39,43H,2-3,5-18,41H2,1,4H3;1H3,(H,2,3,4)/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+;/m1./s1 |
| InChiKey | QAMYWGZHLCQOOJ-WRNBYXCMSA-N |
| InChi | InChI=1S/C40H59NO11.CH4O3S/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41;1-5(2,3)4/h19,23-39,43H,2-3,5-18,41H2,1,4H3;1H3,(H,2,3,4)/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+;/m1./s1 |
| Cas号 | 441045-17-6 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | 固体粉末 |
|---|---|
| 纯度 | 98% Min. |
| 存储 | 短期（几天到几周）为0-4摄氏度，长期（几个月）为-20摄氏度 |
| 可溶性 | 溶于DMSO |
| 处理方式 | |
| 运输条件 | 作为非危险化学品在环境温度下装运。这种产品在正常运输和海关工作期间可以稳定几周. |
| 海关编码 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Gahvari Z, Parkes A. Dedifferentiated Liposarcoma: Systemic Therapy Options. Curr Treat Options Oncol. 2020 Feb 5;21(2):15. doi: 10.1007/s11864-020-0705-7. PMID: 32026050.
2: Jimenez PC, Wilke DV, Branco PC, Bauermeister A, Rezende-Teixeira P, Gaudêncio SP, Costa-Lotufo LV. Enriching cancer pharmacology with drugs of marine origin. Br J Pharmacol. 2020 Jan;177(1):3-27. doi: 10.1111/bph.14876. Epub 2019 Dec 23. PMID: 31621891; PMCID: PMC6976878.
3: Genualdi C, Feinstein SC, Wilson L, Jordan MA, Stagg NJ. Assessing the utility of in vitro microtubule assays for studying mechanisms of peripheral neuropathy with the microtubule inhibitor class of cancer chemotherapy. Chem Biol Interact. 2020 Jan 5;315:108906. doi: 10.1016/j.cbi.2019.108906. Epub 2019 Nov 21. PMID: 31760042.
4: Pizzuti L, Krasniqi E, Barchiesi G, Mazzotta M, Barba M, Amodio A, Massimiani G, Pelle F, Kayal R, Vizza E, Grassadonia A, Tomao S, Venuti A, Gamucci T, Marchetti P, Natoli C, Sanguineti G, Ciliberto G, Vici P. Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. J Cancer. 2019 Oct 12;10(24):5903-5914. doi: 10.7150/jca.35109. PMID: 31762800; PMCID: PMC6856581.
5: Islam B, Lustberg M, Staff NP, Kolb N, Alberti P, Argyriou AA. Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst. 2019 Oct;24 Suppl 2:S63-S73. doi: 10.1111/jns.12334. PMID: 31647152.
6: Fleeman N, Bagust A, Duarte R, Richardson M, Nevitt S, Boland A, Kotas E, McEntee J, Thorp N. Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoecon Open. 2019 Sep;3(3):293-302. doi: 10.1007/s41669-018-0114-z. PMID: 30742256; PMCID: PMC6710448.
7: Bui NQ, Wang DS, Hiniker SM. Contemporary management of metastatic soft tissue sarcoma. Curr Probl Cancer. 2019 Aug;43(4):289-299. doi: 10.1016/j.currproblcancer.2019.06.005. Epub 2019 Jun 15. PMID: 31248634.
8: Pereira RB, Evdokimov NM, Lefranc F, Valentão P, Kornienko A, Pereira DM, Andrade PB, Gomes NGM. Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets. Mar Drugs. 2019 Jun 2;17(6):329. doi: 10.3390/md17060329. PMID: 31159480; PMCID: PMC6627313.
9: Suarez-Kelly LP, Baldi GG, Gronchi A. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments. Expert Opin Pharmacother. 2019 Aug;20(12):1503-1515. doi: 10.1080/14656566.2019.1618271. Epub 2019 May 28. PMID: 31136210.
10: Caparica R, Lambertini M, de Azambuja E. How I treat metastatic triple- negative breast cancer. ESMO Open. 2019 May 13;4(Suppl 2):e000504. doi: 10.1136/esmoopen-2019-000504. PMID: 31231572; PMCID: PMC6555596.
11: Perez-Garcia JM, Cortes J. The safety of eribulin for the treatment of metastatic breast cancer. Expert Opin Drug Saf. 2019 May;18(5):347-355. doi: 10.1080/14740338.2019.1608946. Epub 2019 May 20. PMID: 31107111.
12: Bailey K, Cost C, Davis I, Glade-Bender J, Grohar P, Houghton P, Isakoff M, Stewart E, Laack N, Yustein J, Reed D, Janeway K, Gorlick R, Lessnick S, DuBois S, Hingorani P. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Res. 2019 Apr 15;8:F1000 Faculty Rev-493. doi: 10.12688/f1000research.18139.1. PMID: 31031965; PMCID: PMC6468706.
13: Kasper B. The challenge of finding new therapeutic avenues in soft tissue sarcomas. Clin Sarcoma Res. 2019 Apr 10;9:5. doi: 10.1186/s13569-019-0115-4. PMID: 31007895; PMCID: PMC6457009.
14: O'Shaughnessy J, Kaklamani V, Kalinsky K. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Future Oncol. 2019 May;15(14):1641-1653. doi: 10.2217/fon-2018-0936. Epub 2019 Mar 20. PMID: 30892083.
15: Meyer M, Seetharam M. First-Line Therapy for Metastatic Soft Tissue Sarcoma. Curr Treat Options Oncol. 2019 Jan 24;20(1):6. doi: 10.1007/s11864-019-0606-9. PMID: 30675651.
16: Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H. Therapeutic Targets for Bone and Soft-Tissue Sarcomas. Int J Mol Sci. 2019 Jan 4;20(1):170. doi: 10.3390/ijms20010170. PMID: 30621224; PMCID: PMC6337155.
17: Kano M, Nishisho T, Miyagi R, Chikugo F, Kudo E, Takao S, Iwamoto S, Toki S, Sairyo K. Intimal sarcoma arising from the common iliac artery presenting with artery occlusion : a case report and literature review. J Med Invest. 2019;66(1.2):205-208. doi: 10.2152/jmi.66.205. PMID: 31064943.
18: Abaricia S, Hirbe AC. Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters. Curr Treat Options Oncol. 2018 Oct 25;19(12):64. doi: 10.1007/s11864-018-0590-5. PMID: 30362022.
19: Cortes J, Schöffski P, Littlefield BA. Multiple modes of action of eribulin mesylate: Emerging data and clinical implications. Cancer Treat Rev. 2018 Nov;70:190-198. doi: 10.1016/j.ctrv.2018.08.008. Epub 2018 Aug 21. PMID: 30243063.
20: Jimenez PC, Wilke DV, Costa-Lotufo LV. Marine drugs for cancer: surfacing biotechnological innovations from the oceans. Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e482s. doi: 10.6061/clinics/2018/e482s. PMID: 30133563; PMCID: PMC6096976.
